01 AI-Driven Multimodal Biomarker AnalysisDemand for more comprehensive tumor characterization is encouraging the integration of artificial intelligence with genomic, imaging, and pathology data. Multimodal analysis can identify relationships between molecular alterations, tumor morphology, and treatment response that may not be evident through individual diagnostic methods. This trend is supporting the development of precision oncology platforms that help clinicians refine patient stratification and treatment selection.
02 Personalized Cancer Vaccine DevelopmentAdvances in tumor sequencing are supporting the development of personalized cancer vaccines based on patient-specific neoantigens. These approaches use molecular profiles of individual tumors to identify targets that can stimulate immune responses against cancer cells. This trend is encouraging pharmaceutical and biotechnology companies to expand precision immunotherapy pipelines and explore more individualized treatment strategies.
01 Targeted Therapy AvailabilityThe broader availability of targeted cancer therapies creates demand for diagnostic tests that identify patients with specific genetic mutations and protein expressions. These tests help oncologists match treatment options with the molecular characteristics of individual tumors. For example, HER2 testing identifies breast cancer patients who may benefit from trastuzumab, while EGFR mutation testing guides treatment selection in certain lung cancers. This wider use of targeted therapies supports demand for companion diagnostics, molecular profiling, and specialized laboratory services.
02 Complex Molecular Profiles of Cancer PatientsThe complex molecular profiles of cancer patients increase the need for detailed genomic and biomarker analysis before treatment selection. Differences in mutations within and across tumors make comprehensive testing important for identifying actionable targets and suitable therapies. For example, next-generation sequencing panels can detect multiple mutations in lung cancer samples, helping oncologists evaluate available targeted treatment options. These diagnostic requirements expand demand for advanced sequencing platforms, specialized testing kits, and precision oncology services.
03 Impact Analysis of Key Drivers in Oncology Precision Medicine MarketDriversMarket ImpactBroader Availability of Targeted Cancer TherapiesThe expanding range of drugs designed for specific genetic mutations and protein expressions creates demand for tests that identify eligible patients. Therapies targeting HER2-positive breast cancer and EGFR-mutated lung cancer support the use of companion diagnostics and molecular profiling services.Complex Molecular Profiles of Cancer PatientsVariations in tumor mutations and molecular characteristics create a need for detailed patient-level diagnostic information. Comprehensive genomic testing helps oncologists select suitable treatment options, supporting demand for sequencing platforms, biomarker assays, and specialized laboratory services.Expansion of Oncology Clinical Trial ProgramsPharmaceutical companies require precise biomarker testing to identify patients who meet trial eligibility criteria. Molecular profiling and companion diagnostics support patient screening and stratification, creating demand for specialized testing services from research institutions and clinical trial networks.Greater Focus on Rare and Hard-to-Treat CancersLimited treatment options for rare and advanced cancers encourage the use of molecular testing to identify actionable genetic alterations. Precision diagnostics help clinicians evaluate targeted treatment options, supporting demand for specialized genomic profiling and personalized therapy selection.Growth of Molecular Diagnostic Laboratory NetworksInvestments in specialized laboratories, sequencing equipment, and testing capacity improve access to oncology precision medicine. Expanded laboratory infrastructure supports the supply of genomic profiling, companion diagnostic testing, and biomarker analysis across hospitals and cancer centers.
01 Companion DiagnosticsPharmaceutical companies, oncology drug developers, and diagnostic manufacturers can benefit from companion diagnostics that identify patients most likely to respond to specific cancer treatments. Diagnostic providers can generate revenue through test development, regulatory partnerships, licensing, and testing services, with companies such as Roche Diagnostics and Thermo Fisher Scientific active in this area.
02 Oncology Precision Medicine Data Management PlatformsHospitals, oncology centers, pharmaceutical companies, and clinical research organizations can benefit from specialized platforms that manage and analyze patient, treatment, and clinical data. Technology providers can create revenue through software licensing, data integration, analytics subscriptions, and enterprise contracts, with companies such as IQVIA and Flatiron Health offering relevant oncology data solutions.
June 2026 Roche received U.S. FDA approval for the VENTANA PTEN (SP218) RxDx Assay, the first immunohistochemistry companion diagnostic designed to detect PTEN protein loss in prostate adenocarcinoma. The test helps identify patients who may be eligible for AstraZeneca’s targeted therapy TRUQAP in combination with abiraterone.
May 2026 Tempus AI received U.S. FDA approval for a tumor-only indication for its xT CDx next-generation sequencing platform. The expanded authorization made Tempus the first laboratory to hold companion diagnostic approvals for both tumor-only and tumor-normal comprehensive genomic profiling approaches.
May 2026 Guardant Health received U.S. FDA approval for a new version of Guardant360 Liquid CDx, significantly expanding the genomic footprint of its liquid-biopsy panel. The test integrates genomic and epigenomic information to provide a broader molecular profile of solid tumors from a blood sample.
December 2025 Foundation Medicine reached 100 approved and active companion diagnostic indications across the U.S. and Japan for its FoundationOne CDx and FoundationOne Liquid CDx platforms. The milestone followed regulatory approval in Japan for using FoundationOne CDx to identify patients with NTRK fusion-positive solid tumors who may benefit from targeted therapy.